Lantern Pharma (LTRN) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pluri (PLUR) has outperformed Lantern Pharma (LTRN) over the past year, losing 75.5% versus a loss of 81.9%. Over five years, LTRN leads with a -91.7% price change compared with -95.2% for PLUR. Lantern Pharma is the larger company by market cap ($12.1 million vs $12.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LTRN | PLUR |
|---|---|---|
| Share price | $0.8127 | $0.9532 |
| Market cap | $12.14M | $12.02M |
| 1-day change | -2.08% | -4.68% |
| YTD return | -72.61% | -66.56% |
| 1-year return | -81.92% | -75.49% |
| 5-year return | -91.71% | -95.23% |
| EPS (TTM) | $-1.63 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.68 | $4.87 |
| 52-week low | $0.7603 | $0.85 |
| Distance from 52-week high | -82.63% | -80.43% |
| Analyst consensus | none | — |
| Avg. price target upside | +2053.32% | — |
| Average volume | 180.42K | 24.97K |
| Shares outstanding | 14.94M | 12.61M |
| Employees | 16 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
LTRN vs PLUR FAQ
Which is bigger, Lantern Pharma or Pluri?
Lantern Pharma (LTRN) is larger, with a market capitalization of $12.14M compared with $12.02M for Pluri (PLUR).
Which stock has performed better over the past year, LTRN or PLUR?
PLUR returned -75.49% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Lantern Pharma and Pluri in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Lantern Pharma and Biotechnology: Biological Products (No Diagnostic Substances) for Pluri.